Phase I/II Study of Dasatinib and Osimertinib (AZD9291) in Patients With Advanced Non-small Cell Lung Cancer With EGFR Mutations Read more
Molecular profiling in patients with advanced lung or thymic cancer previously treated with immune checkpoint inhibitor therapy. Read more
A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab- (MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT) Read more
Phase II Trial Of Autologous Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy Of Checkpoint Therapy Resistant Solid Tumors Read more
A Phase 1/2 Study Of Tpx-0131, A Novel Oral Alk Tyrosine Kinase Inhibitor In Subjects With Alk+ Advanced Or Metastatic Nsclc Read more
A Phase 2 Study Of VS-6766 (Dual RAF/MEK Inhibitor) As A Single Agent And In Combination With Defactinib (FAK Inhibitor) In Recurrent KRAS-Mutant (KRAS-MT) Non-Small Cell Lung Cancer (NSCLC) Read more
An Open-Label, Multicenter Phase I Dose Escalation Study To Characterize Safety, Tolerability, Preliminary Antitumor Activity, Pharmacokinetics And Maximum Tolerated Dose Of VIP152 (BAY 1251152) In Subjects With Advanced Cancer Read more
An expanded access protocol for mobocertinib in refractory Non-Small Cell Lung Cancer patients with EGFR exon20 insertion mutations Read more
